secwatch.observer — SEC 8-K summary
======================================

Issuer:     CG Oncology, Inc. (CGON)
CIK:        0001991792
Form:       8-K
Filed at:   2025-03-28T23:59:59+00:00
Accession:  0000950170-25-046335
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CG Oncology reports FY2024 net loss $88.0M; cash $742M; cretostimogene CR rate 75.5%
--------------------------------------------------------------------------------

- Net loss attributable to common stockholders $88.0M ($1.41/share) vs $67.8M ($15.65/share) in FY2023.
- Cash and marketable securities $742.0M as of Dec 31, 2024; $238M oversubscribed equity offering extends runway to H1 2028.
- Cretostimogene monotherapy achieved 75.5% complete response rate in BOND-003; median DoR exceeds 28 months.
- R&D expenses $82.1M in FY2024 (up from $45.8M); G&A expenses $33.7M (up from $9.9M).
- BLA submission for cretostimogene in HR BCG-unresponsive NMIBC anticipated H2 2025; CORE-008 topline data expected H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1991792/000095017025046335/0000950170-25-046335-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1991792/000095017025046335/ck0001991792-20250328.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-046335

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer